Thymalin

Research · Thymalin

Overview

Thymalin is a thymus-derived preparation consisting of low-molecular-weight fractions extracted from calf thymus tissue, developed in the 1970s by Khavinson and Morozov in the Soviet Union. It is one of the earliest compounds in the bioregulator series and has been used as a reference material in immunology, hematopoiesis, and gerontology research. Its composition is a mixture rather than a single defined sequence, and short components including Lys-Glu and Glu-Trp have been identified within it.

Mechanism of action

Thymalin is reported to act on T-lymphocyte maturation and immune regulation. In human hematopoietic stem cell cultures it was reported to reduce expression of CD44 and CD117 and to increase CD28 expression, consistent with stimulated differentiation of CD117-positive precursors toward mature T lymphocytes. Proposed downstream effects include modulation of cytokine expression and thymic lymphoproliferative activity. Because the preparation is a mixture, mechanistic attribution to specific components remains under study. Earlier Soviet-era work also reported effects on platelet aggregation and vascular wall antiaggregation activity in thymectomized rats. Recent work has therefore examined isolated two-residue components, Lys-Glu and Glu-Trp, as candidate active constituents, comparing their gene expression effects with those of the whole preparation.

Key research findings

1. 01

   Human hematopoietic stem cell studies characterized shifts in CD44, CD117, and CD28 expression consistent with T-lymphocyte differentiation.

2. 02

   Rodent studies with transplanted sarcoma characterized changes in tumor growth and in thymic lymphoproliferative activity, tissue basophils, and plasmocytes.

3. 03

   Gene expression work from the originating group examined the contribution of its Lys-Glu and Glu-Trp components to expression of genes involved in inflammatory signaling.

4. 04

   Primary research is published in Russian-language journals and remains uncharacterized in Western clinical databases.

Published references

• Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells

  Khavinson VK et al. — Bull Exp Biol Med, 2020 · PMID: 33237528

• Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo

  Zhukova GV et al. — Bull Exp Biol Med, 2018 · PMID: 29797130

The information above is derived from published preclinical and clinical research. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.